← Leaderboards
Richard G Vile
Mayo Clinic Rochester
$15,977,609
Attributed
$16,659,121
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,659,121 · 14
By mechanism
R01$11,997,903 · 8
P50$2,234,202 · 3
T32$1,363,025 · 1
P30$658,878 · 1
R21$405,113 · 1
Top collaborators
- Brian Patrick O'Neill5 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Evanthia Galanis$13,573,895
- Cornelia M Weyand$30,789,284
- Kah-Whye Peng$11,311,466
- Shruthi Naik$1,310,428
- Kevin G Shim$146,962
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorImmuneTumor AntigensNeoplastic CellViralVirusOncolyticGenesClinicResponseLeadOncolytic VirusesCellsMelanomaMediatingCytokineClinical TrialsCancer TherapyT-LymphocyteRegimenResearch StudyProtocols DocumentationVesicular Stomatitis Indiana VirusBase
Grant awards (64)
Characterizing the role of CSDE1 as a critical co-factor for VSV replication.$391,395
R01 · FY2025 · AI · contact PI
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.$363,713
R01 · FY2025 · CA · contact PI
Project 3$285,839
P50 · FY2025 · CA · contact PI
Project 3$441,978
P50 · FY2024 · CA · contact PI
Characterizing the role of CSDE1 as a critical co-factor for VSV replication.$403,500
R01 · FY2024 · AI · contact PI
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.$345,528
R01 · FY2024 · CA · contact PI
Characterizing the role of CSDE1 as a critical co-factor for VSV replication.$403,500
R01 · FY2023 · AI · contact PI
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.$363,713
R01 · FY2023 · CA · contact PI
Research Training Program in Neuro-Oncology$321,308
T32 · FY2022 · CA
Project 4: Immunovirotherapy$253,206
P50 · FY2022 · CA · contact PI
Novel Strategies to Treat Diffuse Midline Glioma with CAR T Cell Therapy$182,115
R21 · FY2022 · CA · contact PI
Research Training Program in Neuro-Oncology$313,079
T32 · FY2021 · CA
Project 4: Immunovirotherapy$298,617
P50 · FY2021 · CA · contact PI
Novel Strategies to Treat Diffuse Midline Glioma with CAR T Cell Therapy$222,998
R21 · FY2021 · CA · contact PI
Project 4: Immunovirotherapy$315,793
P50 · FY2020 · CA · contact PI
Research Training Program in Neuro-Oncology$244,549
T32 · FY2020 · CA
Project 4: Immunovirotherapy$292,832
P50 · FY2019 · CA · contact PI
Research Training Program in Neuro-Oncology$286,481
T32 · FY2019 · CA
Project 4: Immunovirotherapy$12,136
P50 · FY2019 · CA · contact PI
Project 4: Immunovirotherapy$12,136
P50 · FY2019 · CA · contact PI
Project 4: Immunovirotherapy$321,665
P50 · FY2018 · CA · contact PI
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus$263,940
R01 · FY2018 · CA · contact PI
Research Training Program in Neuro-Oncology$197,608
T32 · FY2018 · CA
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus$263,940
R01 · FY2017 · CA · contact PI
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus$263,940
R01 · FY2016 · CA · contact PI
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus$263,940
R01 · FY2015 · CA · contact PI
Immune Cell Carriers for the Delivery of Oncolytic Viruses to Metastatic Tumors$274,222
R01 · FY2014 · CA · contact PI
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus$263,940
R01 · FY2014 · CA · contact PI
Immune Cell Carriers for the Delivery of Oncolytic Viruses to Metastatic Tumors$265,742
R01 · FY2013 · CA · contact PI
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy$257,291
R01 · FY2013 · CA · contact PI
Flow$120,533
P30 · FY2013 · CA · contact PI
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm$304,127
R01 · FY2012 · CA · contact PI
Immune Cell Carriers for the Delivery of Oncolytic Viruses to Metastatic Tumors$282,704
R01 · FY2012 · CA · contact PI
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy$273,714
R01 · FY2012 · CA · contact PI
Flow$153,920
P30 · FY2012 · CA · contact PI
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm$304,127
R01 · FY2011 · CA · contact PI
Immune Cell Carriers for the Delivery of Oncolytic Viruses to Metastatic Tumors$275,319
R01 · FY2011 · CA · contact PI
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy$273,714
R01 · FY2011 · CA · contact PI
Flow$123,976
P30 · FY2011 · CA · contact PI
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm$313,533
R01 · FY2010 · CA · contact PI
Immune Cell Carriers for the Delivery of Oncolytic Viruses to Metastatic Tumors$291,446
R01 · FY2010 · CA · contact PI
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy$282,179
R01 · FY2010 · CA · contact PI
Flow$131,060
P30 · FY2010 · CA · contact PI
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm$313,533
R01 · FY2009 · CA · contact PI
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy$282,179
R01 · FY2009 · CA · contact PI
Flow$129,389
P30 · FY2009 · CA · contact PI
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm$313,533
R01 · FY2008 · CA · contact PI
T Cell Based Carriers for In Vivo Gene Therapy of Cancer$279,026
R01 · FY2008 · CA · contact PI
Fusogenic Membrane Glycoproteins for Cancer Gene Therapy$283,210
R01 · FY2007 · CA · contact PI
T Cell Based Carriers for In Vivo Gene Therapy of Cancer$279,026
R01 · FY2007 · CA · contact PI
Fusogenic Membrane Glycoproteins for Cancer Gene Therapy$291,668
R01 · FY2006 · CA · contact PI
T Cell Based Carriers for In Vivo Gene Therapy of Cancer$287,360
R01 · FY2006 · CA · contact PI
Fusogenic Membrane Glycoproteins for Cancer Gene Therapy$298,688
R01 · FY2005 · CA
T Cell Based Carriers for In Vivo Gene Therapy of Cancer$294,275
R01 · FY2005 · CA
Fusogenic Membrane Glycoproteins for Cancer Gene Therapy$298,688
R01 · FY2004 · CA
Modulation of Cell Death during Cytotoxic Gene Therapy$257,210
R01 · FY2004 · CA
Modulation of Cell Death during Cytotoxic Gene Therapy$257,210
R01 · FY2003 · CA
FUSOGENIC MEMBRANE GLYCOPROTEINS FOR CANCER GENE THERAPY$253,980
R01 · FY2003 · CA
Modulation of Cell Death during Cytotoxic Gene Therapy$257,210
R01 · FY2002 · CA
FUSOGENIC MEMBRANE GLYCOPROTEINS FOR CANCER GENE THERAPY$253,980
R01 · FY2002 · CA
FUSOGENIC MEMBRANE GLYCOPROTEINS FOR GENE THERAPY$0
P50 · FY2002 · CA
FUSOGENIC MEMBRANE GLYCOPROTEINS FOR CANCER GENE THERAPY$253,980
R01 · FY2001 · CA
FUSOGENIC MEMBRANE GLYCOPROTEINS FOR GENE THERAPY$0
P50 · FY2001 · CA
FUSOGENIC MEMBRANE GLYCOPROTEINS FOR CANCER GENE THERAPY$253,980
R01 · FY2000 · CA